Loading
Life sciences · Preprint
arXiv · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Randomized controlled trials (RCTs) identify treatment effects without confounding but are often small, whereas observational studies (OBS) are large but may be confounded. Many estimators combining a small RCT with a large OBS have been developed for the average treatment effect (ATE) and the conditional ATE (CATE). However, existing ATE estimators either make assumptions on the OBS or do not borrow enough power from them. The CATE has been studied less than the ATE. Existing CATE methods either assume the OBS are unconfounded, rely on a model of the confounding function, or accept bias in exchange for lower variance. We therefore propose a framework that, without special assumptions on the OBS, fuses the OBS and the RCT by preserving the unbiasedness of RCT-based estimation while borrowing power from the large OBS to boost precision. Applying this principle, we build an ATE estimator, AIPW-Fusion, with closed-form weights and confidence intervals, and two CATE learners, DR-Fusion and R-Fusion. Experiments corroborate our findings.